1-Year Results from a Phase 2 Study to Determine Safety and Tolerability of Treating Patients with Light-Chain (AL) Amyloidosis with Cael-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia

Saved in:
Bibliographic Details
Published inBlood Vol. 140; no. Supplement 1; pp. 10127 - 10128
Main Authors Valent, Jason, Liedtke, Michaela, Zonder, Jeffrey A., Tulchinskiy, Mark, Udata, Chandrasekhar, Ramirez, Girly, Szymaniak, Kate, Catini, Julia, Quarta, Candida Cristina
Format Journal Article
LanguageEnglish
Published Elsevier Inc 15.11.2022
Online AccessGet full text

Cover

More Information
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2022-162597